Photo of Anas Younes from astrazeneca.com
Aug 16, 2023, 18:22
Anas Younes: Interesting report, although I disagree with some of the comments.
In a LinkedIn post, Anas Younes, Senior VP, Global Head of Hematology (Early and Late Stage), Oncology R&D at AstraZeneca recently wrote:
”Interesting report, although I disagree with some of the comments. Accelerated approval is a very important process to quickly bring impactful medicines to patients with unmet medical needs, such as cancer. Of course, there is always room for improvement.”
Source: Anas Younes/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59
Nov 13, 2024, 10:54